BLID is a drug-responsive target of FOXO3a and multi-omics analysis reveals survival mechanisms and therapeutic vulnerabilities in BLID-deficient breast cancer cells

Sivaramakrishna Yadavalli(Georgetown University), Usha N. Kasid(Georgetown University Medical Center)
Oncology Letters
June 24, 2025
Cited by 0


Related Papers